Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects

Pharmacological Reports

Volumn 61, Issue 5, 2009, Pages 843-850

  He, Xiao Jing ^a   Zhao, Li Mei ^a   Qiu, Feng ^a   Sun, Ya Xin ^a   Li Ling, Jesse ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NORTHEASTERN UNIVERSITY   (China)

Author keywords

ABCB1; Azithromycin; Pharmacokinetics; Single nucleotide polymorphism (SNP)

Indexed keywords

AZITHROMYCIN; MULTIDRUG RESISTANCE PROTEIN 1;

ABSENCE OF SIDE EFFECTS; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; ETHNICITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70549088050     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70140-9     Document Type: Article

References (54)

1. Amacher DE, Schomaker SJ, Retsema JA: Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother, 1991, 35, 1186-1190.
2. Amsden GW: Erythromycin, clarithromycin and azithromycin: are the differences real? Clin Ther, 1996, 18, 56-72.
3. Amsden GW, Ballow CH, Forrest A: Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin Drug Invest, 1997, 13, 152-161.
4. Amsden GW, Nafziger AN, Foulds G, Cabelus LJ: A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol, 2000, 40, 1522-1527. (Pubitemid 30846556)
5. Backman JT, Aranko K, Himberg JJ, Olkkola KT: A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol, 1994, 46, 551-555.
6. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C: Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther, 2001, 70, 311-316.
7. Borst P, Schinkel AH, Smith JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW et al.: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther, 1993, 60, 289-299.
8. Bosch TM, Meijerman I, Beijnen JH, Schellens JH: Genetic polymorphisms of drug-metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet, 2006, 45, 253-285. (Pubitemid 43327492)
9. Charles L, Segreti J: Choosing the right macrolide antibiotic. A guide to selection. Drugs, 1995, 53, 363-371.
10. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics, 2003, 13, 89-95. (Pubitemid 36259588)
11. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem, 1990, 38, 1277-1287.
12. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Bertino JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA, 1989, 86, 695-698. (Pubitemid 19037807)
13. Evans WE, McLeod HL: Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med, 2003, 348, 538-549
14. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature, 2004, 429, 464-468. (Pubitemid 38715141)
15. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999, 286, 487-491.
16. Fojo AT, Ueda K, Salmon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA, 1987, 84, 265-269. (Pubitemid 17013615)
17. Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother, 1990, 25 Suppl A, 73-82.
18. Garey KW, Peloquin CA, Godo PG, Nafziger AN, Amsden GW: Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, aclarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother, 1999, 43, 1152-1155.
19. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol, 2002, 54, 610-616. (Pubitemid 36002588)
20. Gottesman MM, Pastan I, Ambudkar SV: P-glycoprotein and multidrug resistance. Curr Opin Genet Dev, 1996, 6, 610-617.
21. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P et al.: Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther, 1998, 64, 278-285. (Pubitemid 28462288)
22. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000, 97, 3473-3478.
23. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K: Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res, 2002, 19, 1581-1585.
24. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res, 2002, 62, 4955-4962. (Pubitemid 34984419)
25. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S et al. : Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther, 2002, 72, 584-594.
26. Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics, 2000, 1, 15-26.
27. Keller F, Rietbrock N: Bioavailability of digoxin: some pitfalls and problems. Int J Clin Pharmacol Biopharm, 1977, 15, 549-556. (Pubitemid 8241131)
28. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics, 2001, 2, 51-64.
29. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 2001, 70, 189-199. (Pubitemid 32777772)
30. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D et al.: Sequence diversity and haplotype structure in the human ABCB1 (MDRl, multidrug resistance transporter) gene. Pharmacogenetics, 2003, 13, 481-494. (Pubitemid 37034590)
31. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther, 2002, 72, 209-219. (Pubitemid 35034499)
32. Kurzawski M, Pawlik A, Górnik W, Droździk M: Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep, 2006, 58, 35-40.
33. Leonard GD, Fojo T, Bates SE: The role of ABC transporters in clinical practice. Oncologist, 2003, 8, 411-424. (Pubitemid 37238869)
34. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther, 2004, 75, 13-33. (Pubitemid 38130115)
35. Michot JM, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM: Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob Agents Chemother, 2004, 48, 2673-2682. (Pubitemid 38823441)
36. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M et al.: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther, 2002, 71, 297-303. (Pubitemid 34311459)
37. Nakamura Y, Ikeda S, Furukawa T, Sumizawa T, Tani A, Akiyama S, Nagata Y: Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun, 1997, 235, 849-853. (Pubitemid 27326573)
38. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res, 2001, 18, 1400-1404. (Pubitemid 32977244)
39. Sakaeda T, Nakamura T, Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull, 2002, 25, 1391-1400. (Pubitemid 39663152)
40. Seral C, Michot JM, Chanteux H, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother, 2003, 47, 1047-1051. (Pubitemid 36254233)
41. Singlas E.: Clinical pharmacokinetics of azithromycin. Pathol Biol (Paris), 1995, 43, 505-511.
42. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res, 1988, 48, 1926-1929.
43. Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baka K, Kitaichi K et al.: Possible involvement of the drug transporters P-glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother, 2004, 48, 809-814. (Pubitemid 38280329)
44. Takane H, Kobayashi D, Hirota T, Kiqawa J, Terakawa N, Otsubo K, Ieiri I: Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther, 2004, 311, 1179-1187. (Pubitemid 39612726)
45. Tan EK, Chan DK, Ng PW, Woo J, Teo YY, Tang K, Wong LP et al.: Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol, 2005, 62, 460-464. (Pubitemid 40349484)
46. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 2001, 297, 1137-1143. (Pubitemid 32472514)
47. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA, 1987, 84, 7735-7738.
48. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol, 2003, 58, 809-812.
49. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P et al.: Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther, 2003, 73, 51-60.
50. Wacher VJ, Wu CY, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog, 1995, 13, 129-134.
51. Xue-Min Z, Jie L, Juan G, Quan-Sheng Y, Wen-Yan W: Determination of azithromycin in human plasma by LC-MS-MS and its pharmacokinetics. Pharmazie, 2007, 62, 255-257. (Pubitemid 46596367)
52. Yeates RA, Laufen H, Zimmermann T: Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharm Ther, 1996, 34, 400-405. (Pubitemid 26305815)
53. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A: Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneim-Forsch, 1996, 46, 213-217.
54. Zuckerman JM, Kaye KM: The newer macrolides azithromycin and clarithromycin. Infec Dis Clin North Am, 1995, 9, 731-745.